CPCarlotta Pipolo

Carlotta Pipolo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carlotta Pipolo has a total of 341 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Infraorbital Ethmoid Cells and Sinonasal Opacification: A Multicenter Cross-Sectional Radiological Evaluation

    by Chiara Spoldi, Umberto D'AGostino Fiorenza, Cavallo Giovanni, Erika Crosetti, Gian Luca Fadda, Carlotta Pipolo, Giovanni Felisati, Alberto Maria Saibene, Federica Vultaggio, Giancarlo Cacioppo

    Background: Infraorbital ethmoid cells, also known as Haller’s cells (HCs), are anatomical variants whose impact on sinus drainage and ventilation remains uncertain. The purpose of this study was to assess the prevalence of HCs and their correlation with sinus and ostiomeatal complex opacification in a large cohort of patients, thus settling the debate raised by previous studies’ conflicting results. Methods: A multicenter cross-sectional radiological analysis was conducted on adult patients who underwent maxillofacial computed tomography scans from January 2019 to December 2020. A radiological database containing 2332 scans were reviewed, selecting 1853 suitable patients. Evaluations of the presence of unilateral or bilateral HCs, septal deviation, and the extent of sinus opacifications were conducted independently on radiographic images. Results: Haller’s cells were present in 12.25% of cases. The occurrence of this anatomical variation did not significantly correlate with either the presence or the degree of maxillary, anterior/posterior ethmoid, and ostiomeatal complex opacifications. However, patients with HCs were generally younger at diagnosis and exhibited a higher incidence of septal deviation than those without infraorbital ethmoid cells. Conclusion: The findings reaffirm the prevalence of HCs as previously documented. Thanks to the selection of a large sample of patients, the investigation concluded that the presence of HCs on radiographic images cannot be considered a determinant for sinus disease. Cite this article as: Spoldi C, Fiorenza UD, Vultaggio F, et al. Infraorbital ethmoid cells and sinonasal opacification: a multicenter crosssectional radiological evaluation. B-ENT. 2025;21(2):80-85.

  • Influence of Multiple Prior Endoscopic Sinus Surgeries on Dupilumab Efficacy Including Smell Function in the DUPIREAL Population

    by Eugenio De Corso, Claudio Montuori, Elena Cantone, Giorgia Carlotta Pipolo, Daniela Lucidi, Ernesto Pasquini, Ignazio La Mantia, Rodolfo Francesco Mastrapasqua, Gabriele De Maio, Gian Luca Fadda, et al.

    Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition that significantly reduces the quality of life due to nasal obstruction, loss of smell and rhinorrhea. Although endoscopic sinus surgery offers relief of symptoms and improvement of quality of life, recurrences are common and multiple surgeries are often required. The aim of this post hoc analysis is to verify the hypothesis that previous multiple surgeries may be associated with poor outcomes with dupilumab in a real‐life setting in terms of quality of life, reduction in nasal polyps and improvement of olfaction. Methods: This is a post hoc analysis of the Phase IV real‐life multicentre DUPIREAL study in patients with severe uncontrolled CRSwNP treated with dupilumab 300 mg every 2 weeks for 12 months. Inclusion criteria included adherence to treatment and olfactory evaluation measured by Sniffin' Sticks Identification Test 16 (SSIT‐16). Statistical analyses included multivariate regression, evaluating correlations between baseline factors and poor outcomes in terms of NPS ≥ 4, SNOT‐22 ≥ 30 and SSIT‐16 ≤ 12. Results: Higher NPS at baseline was associated with an increased risk of NPS > 4 at 12 months, whereas a higher number of previous surgeries is associated with a higher probability of lower NPS. Notably, a greater number of previous surgeries was independently associated with incomplete recovery of smell, and surgery‐naïve patients had a higher likelihood of achieving complete olfactory recovery. Dupilumab treatment led to a remarkable improvement in olfactory function, with anosmia rates decreasing from 60.2% to 3.3% after 1 year, although in our series, nearly half of the patients still exhibited residual olfactory impairment. Conclusions: This post hoc analysis highlights the efficacy of dupilumab for the treatment of CRSwNP in real life. Multivariate analysis revealed that multiple prior surgeries negatively impact outcomes with dupilumab during the first year of treatment, especially in terms of olfactory recovery.


  • Open Access

    Do We Have Any Environmental or Perinatal Factor Which May Predispose for Paediatric Airways Diseases? An Italian Population Prospective Study

    by Cecilia Rosso, Federica Turati, Alberto Maria Saibene, Elvira Verduci, Giuseppe Banderali, Monica Ferraroni, Giovanni Felisati, Carlotta Pipolo

    Background: Paediatric airway diseases such as asthma, allergies, rhinitis, upper respiratory tract infections and acute otitis media are major health challenges for children globally. The prevalence of these conditions has been increasing, impacting children's quality of life, educational attainment and imposing a substantial economic burden. Objectives: This longitudinal prospective study investigated the prevalence rates and environmental links associated with paediatric airway diseases in the first 3 years of life in 241 newborns, with the goal of contributing to early detection, prevention and management strategies. Methods: Structured questionnaires were administered to parents at birth, 1 year and 3 years of age. Data on socioeconomic factors, pregnancy and delivery characteristics, parental smoking, breastfeeding, childcare attendance and children's health history were collected. Skin prick tests were conducted in year 3 to assess allergic sensitisation. Results: Two hundred seven patients completed three‐year follow‐up. Factors such as having siblings, exclusive breastfeeding and attending kindergarten were associated with increased risks of certain diseases at 1 and 3 years. Smoking exposure appeared protective against wheezing in the first year. Breastfeeding showed mixed results, with protective effects against URTIs at 1 year but a potential risk factor for asthma at 1 year. Kindergarten attendance was associated with increased risks of URTIs and AOM at 3 years but appeared protective against inhalant allergies. Conclusion: The study highlighted the complex interplay of various factors in the development of paediatric airway diseases. Further research is needed to refine our understanding of these factors and their impact on paediatric diseases.

  • Top Cited Papers

    Two‐Year Turning Point With Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Control, Remission, and Tapering Dosage

    by Eugenio De Corso, Claudio Montuori, Carlotta Pipolo, Ignazio La Mantia, Ernesto Pasquini, Angelo Ghidini, Veronica Seccia, Giancarlo Ottaviano, Elena Cantone, Giulia Dané, et al.

    Background: Dupilumab is an effective treatment for severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP). Most real‐life studies have been conducted on small patient cohorts for up to 1 year. Methods: This ambispective, multicentric, 2‐year‐long study evaluated dupilumab effectiveness (including treatment response, disease control, and remission) and safety in severe, uncontrolled CRSwNP patients from the DUPIREAL Italian study centers. Results: The study involved 926 patients. At 24 months, median nasal polyp score (NPS), nasal obstruction visual analogue scale (VAS), Sino‐nasal Outcome Test‐22 (SNOT‐22), and olfaction improved from baseline (all p < 0.0001). Patients with NPS > 4, and/or SNOT‐22 > 30, and/or Sniffin’ Sticks Identification Test‐16 (SSIT‐16) < 12 at 12 months demonstrated improvements in these outcomes over the second year. Overall, 18.7% of patients extended the dupilumab interdose interval to every 4 weeks (q4w). Notably, 91.2% of patients were “good‐to‐excellent” responders based on EPOS/Euforea criteria. Given the absence of standardized definitions for disease control and remission, we proposed different sets of criteria reporting results from different scenarios. Remission analysis is clinically important as it helps define treatment success and long‐term therapeutic goals. Most adverse events were mild‐to‐moderate; 2.4% of patients discontinued treatment due to safety concerns. Conclusions: This is the largest real‐life study evaluating dupilumab in CRSwNP over 2 years. Dupilumab showed sustained effectiveness, with progressive improvements across all clinical outcomes. Dupilumab tapering did not compromise outcomes; treatment continuation allowed meaningful clinical benefits in late responders. Two‐year rates of disease control and remission are clinically relevant, although standardized criteria to assess these outcomes are needed.


  • Leveraging Computational Geometry for Data Augmentation in Medical Flow Fields Classification

    by Riccardo Margheritti, Andrea Schillaci, Carlotta Pipolo, Maurizio Quadrio, Giacomo Boracchi


  • Open Access

    Proposal of a New Composite Score (DAMADECO) to Simultaneously Evaluate Asthma and CRSwNP Severity in Comorbid Patients

    by Maria D’amato, Patrizio Pasqualetti, Elena Cantone, Marco Caminati, Matteo Bonini, Fabiano Di Marco, Carlotta Pipolo, Veronica Seccia, Giovanni Sotgiu, Eugenio De Corso

    Background: Asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are chronic respiratory conditions that frequently coexist. However, an integrated assessment tool for both conditions is currently lacking. This study aimed to develop and preliminarily evaluate a composite score capable of simultaneously assessing asthma and CRSwNP in comorbid patients. Methods: An expert panel comprising three pulmonologists, one allergist/clinical immunologist, and four ear, nose and throat (ENT) specialists developed a tool to capture asthma and CRSwNP severity. The tool (D’Amato-De Corso score, or DAMADECO score) incorporates eight parameters, four specific to asthma and four specific to CRSwNP, to assign individual scores for each condition. A composite score is then calculated to reflect the overall disease burden (ranging from −8: poor control and +8: optimal control). A retrospective pilot study was conducted to evaluate the tool. Results: The DAMADECO composite score was applied to 21 comorbid patients. The mean partial scores for asthma and CRSwNP were −1.57 and −1.67, respectively, with a mean total composite score of −3.24. A total of 13 out of 21 patients had uncontrolled domains in both diseases, while fewer patients had only uncontrolled domains in asthma (1/21) or CRSwNP (6/21). The DAMADECO score also allows researchers to track disease progression and monitor treatment effectiveness. Conclusions: The preliminary results suggest that the DAMADECO score is a promising tool for simultaneously assessing asthma and CRSwNP, addressing the unmet need for an integrated approach to comorbid respiratory diseases. Further validation studies are needed to validate the tool in larger patient populations.


  • Open Access

    Glass‐blowing, brass‐playing, and other laryngocele etiologies: Fact or fiction? A systematic literature review

    by Giorgia Pugliese, Leonardo Giudici, Alberto Scotti, Alberto Maccari, Paolo Lozza, Antonino Maniaci, Giorgia Carlotta Pipolo, Giovanni Felisati, Alberto Maria Saibene

    Objective: Laryngocele is a rare condition, which can be congenital or acquired, characterized by an abnormal dilatation of the laryngeal ventricle filled with air. A correlation between laryngocele formation and increased intralaryngeal pressure has been postulated, as much as a frequent coexistence with laryngeal carcinoma. Despite this, systematic research on its potential etiology is still limited up to date. Methods: We carried out a systematic an electronic search on the MEDLINE, Embase, Web of Science, Cochrane Library, Scopus, and ClinicalTrials.gov databases for all articles related to laryngocele or laryngopyocele. The authors performed a PRISMA‐compliant systematic review across multiple databases including all studies published until February 7, 2023, focusing on laryngocele etiology. Case reports and articles in languages other than English were excluded. The authors recorded etiology, age of patients, male‐to‐female ratio, history of smoking, symptoms, management, and overall follow‐up. Results: The majority of publications related to laryngocele are case reports and case series. We found a total of 10 articles correctly reporting etiologies, the majority of which included only a limited number of patients. Most case series explored the association of laryngocele and laryngeal cancer. Other reported etiologies were wind instruments' playing, cricohyoidoepiglottopexy's execution, amyloidosis, and chronic constipation. Some cases of congenital laryngocele were also reported. Conclusions: Actual knowledge concerning laryngocele etiology appears—based on literature studies—inferential at best. The association between laryngocele and laryngeal cancer is, on the other hand, well‐established and must be taken into account when evaluating patients with this condition. Wider and prospective data collections should allow further insight into this condition and its pathogenesis.

  • Open Access

    Pediatric Odontogenic Sinusitis: A Systematic Review

    by Cecilia Rosso, Anastasia Urbanelli, Chiara Spoldi, Giovanni Felisati, Giancarlo Pecorari, Carlotta Pipolo, Nicolò Nava, Alberto Maria Saibene

    Background: Pediatric odontogenic sinusitis (PODS) is a rare condition with limited research on its clinical features, diagnostic criteria, and treatment options. The current guidelines on pediatric rhinosinusitis do not mention a possible dental origin of the disease. This systematic review aims to summarize and analyze the existing literature on PODS, focusing on epidemiology, etiology, diagnostic tools, complications, treatment options, and outcomes. Methods: A systematic review was conducted following PRISMA reporting guidelines. Electronic searches were performed in multiple databases using keywords related to PODS and therapeutic strategies. Original articles reporting data on treatment outcomes for PODS were included. Results: The review highlighted the scarcity of high-quality evidence on PODS. The literature mainly consists of case reports and low-grade evidence studies. Limited data on the epidemiology, etiology, diagnostic tools, complications, and treatment outcomes of PODS in children are available. Conclusions: Further research is needed to better understand the clinical features, diagnosis, and treatment of PODS in pediatric patients. High-quality studies are required to establish evidence-based guidelines for the management of this condition, especially given the apparently high rate of complications when compared to adult ODS.


  • Multidisciplinary Decision-Making—ITAlian Consensus After Two Years of Real Practice on the Management of Severe Uncontrolled CRSwNP by Biologics (ITACA Study)

    by Eugenio De Corso, Carlotta Pipolo, Marco Caminati, Elena Cantone, Veronica Seccia, Lorenzo Cecchi, Eustachio Nettis, Massimiliano Garzaro, Giancarlo Ottaviano, Matteo Gelardi, et al.

    Purpose of Review We aimed to reach an Italian multidisciplinary consensus on some crucial aspects of treatment decision making in CRSwNP, following 2 years of clinical experience in order to support specialists in the management of CRSwNP in clinical practice. We addressed issues relating to therapeutic decision-making and shared criteria for the treatment choice, as well as appropriate timing and criteria for evaluating treatment response, and highlighted the need for repeated multidisciplinary assessments. Recent Findings A national survey has been conducted recently to understand how rhinology practice has changed in Italy with the advent of biologics and how this affects patients with uncontrolled, severe CRSwNP. Despite the many published consensus documents, practical recommendations, and protocols on the use of biologics in CRSwNP, heterogenous behaviors in practice are still observed mainly conditioned by the novelty of the topic. Summary The consensus procedure followed a modified Delphi approach. The scientific board included 18 otorhinolaryngologists and 8 allergists, who selected the 4 main topics to be addressed and developed overall 20 statements. Consensus on these statements was sought by a larger group of 48 additional experts, through two rounds of voting, the first web-based, the second in presence with discussion and possible refinement of the statements. The statements reaching an average score ≥ 7 at the second voting round were approved. Five statements were proposed for each of the following topics: baseline evaluation of patients eligible for biologic therapy; choice between different therapeutic options; assessment of the response to biologic treatment; multidisciplinary management. At the first voting round, 19 out of the 20 statements reached a mean score ≥ 7. Following the discussion and a few consequent amendments, at the second round of voting all the 20 statements were approved.


  • Open Access

    Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP

    by Cecilia Rosso, Eugenio De Corso, Valerio Conti, Letizia Nitro, Alberto Maria Saibene, Elena Parazzini, Rocco Rinaldo, Sabrina De Pascalis, Flavio Arnone, Stefano Centanni, et al.

    Purpose: Nowadays, several efficacious biologic drugs are used for severe asthma with or without chronic rhinosinusitis with nasal polyps (CRSwNP). However, it has been observed that not all comorbid patients (asthma/CRSwNP) receiving biologic treatment for asthma experience satisfactory control of both conditions equally. Methods: We selected 20 patients who had both severe asthma and comorbid CRSwNP under biological treatment with benralizumab, omalizumab or mepolizumab with adequate control of asthma but inadequate control of nasal symptoms. Patients were switched to dupilumab and outcomes were evaluated at baseline (T0), at 3 months (T1), at 6 months (T2), at 12 months (T3) and finally at 18 months (T4). Data were collected at each time point including blood tests measuring eosinophil levels and total IgE, SNOT22, ACT, NPS score, rhinomanometry, olfactory testing, and nasal cytology. Results: The results showed an overall improvement in all the outcomes. Peripheral eosinophilia was observed consistently with existing literature. All patients registered an improvement in sinonasal outcomes, while only one patient had a worsening of asthma. Three patients interrupted the therapy due to various causes: poor asthma control, onset of psoriasis and thrombocytopenia. Conclusions: The response to a biologic treatment for CRSwNP control may be heterogenous and it seems that patients may benefit from switching improving control in equal measure in the upper and lower airway. Further studies to explore the endotype/phenotype which best fits with each biologic are mandatory to personalize the therapy.